Additionally, the 36-month beta value for VIR is 0.47. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VIR is 87.87M and currently, short sellers hold a 5.63% ratio of that float. The average trading volume of VIR on August 23, 2024 was 1.12M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VIR) stock’s latest price update
The stock of Vir Biotechnology Inc (NASDAQ: VIR) has decreased by -4.04 when compared to last closing price of 8.67.Despite this, the company has seen a loss of -3.93% in its stock price over the last five trading days. zacks.com reported 2024-08-06 that The consensus price target hints at a 258.4% upside potential for Vir Biotechnology (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
VIR’s Market Performance
Vir Biotechnology Inc (VIR) has experienced a -3.93% fall in stock performance for the past week, with a -17.62% drop in the past month, and a -26.82% drop in the past quarter. The volatility ratio for the week is 3.94%, and the volatility levels for the past 30 days are at 4.65% for VIR. The simple moving average for the past 20 days is -9.02% for VIR’s stock, with a -14.26% simple moving average for the past 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at -10.59% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.30% of loss for the given period.
Volatility was left at 4.65%, however, over the last 30 days, the volatility rate increased by 3.94%, as shares sank -21.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.69% lower at present.
During the last 5 trading sessions, VIR fell by -3.93%, which changed the moving average for the period of 200-days by -5.02% in comparison to the 20-day moving average, which settled at $9.03. In addition, Vir Biotechnology Inc saw -17.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from Ramasastry Saira, who sale 4,000 shares at the price of $10.95 back on Jun 11 ’24. After this action, Ramasastry Saira now owns 14,619 shares of Vir Biotechnology Inc, valued at $43,789 using the latest closing price.
De Backer Marianne, the Chief Executive Officer of Vir Biotechnology Inc, sale 72,995 shares at $9.46 during a trade that took place back on Apr 03 ’24, which means that De Backer Marianne is holding 678,457 shares at $690,365 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -6.73 for the present operating margin
- 0.8 for the gross margin
The net margin for Vir Biotechnology Inc stands at -6.7. The total capital return value is set at -0.31. Equity return is now at value -29.78, with -24.69 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.94. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -2032.19.
Currently, EBITDA for the company is -641.55 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 13.04. The receivables turnover for the company is 10.02for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.51.
Conclusion
In conclusion, Vir Biotechnology Inc (VIR) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
